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p53-dependent G1 and G2 cell cycle checkpoints are activated in
response DNA damage that help to maintain genomic stability.
p53 also helps to protect cells from damage that occurs during
S phase, for example, when the cells are starved for DNA
precursors or irradiated with a low dose of UV. p53 is activated
in normal cells starved for pyrimidine nucleotides by treatment
with N-(phosphonacetyl)-L-aspartate (PALA). The treated cells
progress through a first S phase with kinetics similar to those of
untreated cells. However, the DNA of the treated cells begins to
become damaged rapidly, within 12 h, as revealed by a comet
assay, which detects broken DNA, and by staining for phosphor-
ylated histone H2AX, which accumulates at sites of DNA dam-
age. Because the cells survive, the damage must be reversible,
suggesting single-strand breaks or gaps as the most likely
possibility. The transiently damaged DNA stimulates activation
of ATR and CHK1, which in turn catalyze the phosphorylation
and accumulation of p53. Although PALA-induced DNA damage
occurs only in dividing cells, the p53 that is activated is only
competent to transcribe genes such as p21 and macrophage
inhibitory cytokine 1 (whose products regulate G2 and G1 or S
phase checkpoints, respectively) after the cells have exited the
S phase during which damage occurs. We propose that p53 is
activated by stimulation of mismatch repair in response to the
misincorporation of deoxynucleotides into newly synthesized
DNA, long before the lack of pyrimidine nucleoside triphos-
phates causes the rate of DNA synthesis to slow appreciably.
macrophage inhibitory cytokine 1  p21  N-(phosphonacetyl)-L-aspartate 
S phase
The tumor suppressor p53 is essential for the normal responsesto DNA damage that help to maintain genomic stability.
Extensive DNA damage leads to the irreversible arrest or
apoptosis of normal cells, preventing cells in which mutations are
likely to have occurred from propagating. In most human
tumors, the normal negative regulatory function of p53 is
compromised, either by direct mutation, deletion or inactivation
of p53 itself, or disruption of signaling pathways that activate p53
or respond to activated p53, the ‘‘p53 network’’ (1). In contrast,
arrest of DNA or RNA synthesis or depletion of pyrimidine
nucleotide pools leads to reversible arrest, appropriate to pro-
tecting cells, rather than disposing of them to protect the
organism. Cell-protective p53-dependent cell cycle checkpoints
are activated in response to arrest of DNA synthesis (2, 3) or
arrest of mitosis (4, 5). Fibroblasts from normal individuals or
Li-Fraumeni patients arrest stably when treated with N-
(phosphonacetyl)-L-aspartate (PALA), an inhibitor of pyrimi-
dine nucleotide synthesis (6), and remain viable for weeks at a
time (7). However, this property is lost in post-crisis Li-Fraumeni
fibroblasts when the remaining wild-type p53 allele is lost (8). In
one such cell line, MDAH041, restoration of wild-type p53
restores the normal response to PALA (8). As shown by several
laboratories, (7–9), the ability of human and mouse cells to give
rise to PALA-resistant colonies depends on inactivation of the
p53 response pathway. Thus, normal cells that can arrest stably
and reversibly in PALA do not give resistant colonies, whereas
most cells defective in p53 die rapidly in PALA but do give rise
to rare PALA-resistant cells through amplification of the CAD
gene (10).
Linke et al. (2) showed that normal human fibroblasts do not
incur extensive DNA damage as indicated by the absence of
chromosomal aberrations such as chromatid breaks, chromo-
some exchanges, and double minute chromosomes upon treat-
ment with PALA. Rodent and human fibroblasts with wild-type,
functional p53 arrest in the cell cycle, preventing them from
synthesizing DNA under adverse conditions (8, 11). Previously,
we showed that p53-dependent arrest within S phase is revealed
in cell lines that either have relatively low levels of p53 or lack
expression of p21, a major mediator of arrest in G1 or G2 (8, 12).
In contrast, cells lacking p53 continue DNA synthesis in the
presence of PALA, thereby incurring DNA damage that acti-
vates a signaling cascade involving caspase activation, cyto-
chrome c release, and finally apoptosis (13). Furthermore,
activated p53 stimulates the secretion of the cytokine macro-
phage inhibitory cytokine 1 (MIC-1), which mediates reversible
and protective cell cycle arrest in S phase (13). However, it is not
known how p53 is activated in cells starved for nucleotides. We
now find that cells starved for pyrimidine nucleotides, while
attempting to progress through S phase, incur limited, reversible
DNA damage that provides a signal for the phosphorylation and
activation of p53 through the ATR–CHK1 pathway.
Results
DNA Damage in Cells Starved for Pyrimidine Nucleotides. Unbal-
anced pools of nucleotides lead to misincorporation during DNA
synthesis, activating the mismatch repair process, which includes
the creation of a repair patch, a transient form of DNA damage
(14). We used two sensitive assays to investigate whether treat-
ment with PALA indeed leads to DNA damage capable of
providing a signal that activates p53. Normal BJ fibroblasts
treated with 250 M PALA were analyzed by comet staining, an
effective method for evaluating DNA damage. The denatured,
cleaved DNA fragments migrate out of the cell under the
influence of an electric field, resulting in a distinct tail, whereas
undamaged DNA migrates more slowly and remains within the
confines of the nucleus (15). This test detects both single- and
double-stranded DNA breaks. A time-dependent increase in
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comet-positive cells was evident, beginning at 12 h after
addition of PALA (Fig. 1A), and almost 56% of the cells were
positive by 48 h. Because phosphorylated histone H2AX
(H2AX) accumulates at sites of broken DNA (16), we also
examined the status of H2AX after PALA treatment. BJ cells
treated with 250 M PALA for 1–48 h were stained for this
protein and examined by confocal microscopy. As early as 2–3 h
after PALA addition there was an increase in the number of
H2AX-positive cells and approximately half of these cells were
positive by 24 h (Fig. 1B). Linke et al. (2) showed that pyrimidine
nucleotide pools and the rate of RNA synthesis decline to50%
of their initial values 12 h after treatment of normal human
fibroblasts with PALA. Together, these observations strongly
support the conclusion that cells in which the pyrimidine nucle-
otide pools are just beginning to be depleted in response to
PALA still do incur DNA damage that is detectable by two
different sensitive assays.
Activation and Phosphorylation of p53 in Response to PALA Uses ATR
and CHK1. The observation that treatment with PALA does lead
to detectable DNA damage made it important to investigate how
such damage might lead to p53 induction. Total lysates from
PALA-treated BJ cells were analyzed for the total amount of p53
and phosphorylation of serine residues of p53. There was an
appreciable increase in the amount of p53 protein and in the
amount of the p53-dependent gene product p21 (Fig. 2A).
Time-dependent phosphorylation of p53 serine residues 15 and
46 was also observed upon treatment with PALA (Fig. 2B). As
is well known, treatment of BJ cells with the DNA-damaging
drug camptothecin resulted in p53 stabilization and phosphor-
ylation of p53 (Fig. 2C). Treatment with nutlin, which induces
p53 without phosphorylation by inhibiting its binding to the
negative regulator mdm2 (17), served as a negative control.
These observations demonstrate that a signal generated by
starvation for pyrimidine nucleotides leads to the phosphoryla-
tion and accumulation of p53, confirming the observations of
many laboratories.
Because the signal from damaged DNA can lead to the
phosphorylation of CHK1, to gain further insight into the
mechanism of stabilization and activation of p53 by PALA we
analyzed the phosphorylation of serine residues 345 and 317 of
CHK1 by using specific antibodies. PALA treatment did lead to
the phosphorylation of serine residues 345 (Fig. 3A) and 317
(data not shown). Therefore, modification and stabilization of
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Fig. 1. DNA damage in cells starved for pyrimidine nucleotides. (A) (Left) DNA damage, measured by comet assay in BJ cells treated with 250 M PALA. (Right)
Represented are comet-positive cells. One hundred cells were counted for each time point. (B) pH2AX in BJ cells treated with 250 M of PALA. (Left) A
representative field of pH2AX-positive cells is shown. (Inset) At higher magnification showing distinct punctate staining. One hundred cells were counted for
each time point. (Right) Represented are pH2AX-positive cells counted for each time point. (Magnifications: 20; Insets, 40.)
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Fig. 2. Induction and phosphorylation of p53 in cells starved for pyrimidine
nucleotides. Western analysis of p53 in BJ cells treated with 250 M PALA is
shown. Treatment with camptothecin (a known DNA-damaging agent) and
nutlin (activator of p53 with out DNA damage) served as controls.
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p53 in response to transient DNA damage caused by PALA
treatment is likely to involve the CHK1–ATR pathway. To test
the involvement of ATR and ATM, we treated ATR WT, ATR
kinase-dead (KD) cells (Fig. 3B), and ATM-null primary fibro-
blasts (Fig. 3C) with PALA for 12, 24, or 48 h. Exposure to
PALA led to increased expression of total p53 (Fig. 3 B and C)
and phosphorylation of p53 at serine 6 (data not shown) in ATR
WT and ATM-null cells but not in ATR KD cells. Phosphory-
lation of CHK1 at serine 317 (data not shown) and serine 345
(Fig. 3 B and C) was also observed in ATR WT and ATM-null
cells but not in ATR KD cells. To investigate further the
involvement of CHK1, cells were pretreated with 300 nM
UCN-01, a CHK1 inhibitor (18), for 45 min before treating them
with 250 M PALA (Fig. 3A). p53 induction and phosphoryla-
tion of CHK1 occurred only in control cells, and there was no
significant increase in p53 levels in UCN-01-treated cells. The
higher levels of CHK1-pSer345 seen in the presence of UCN-01
are caused by stabilization of this phosphorylation by this
inhibitor (18). We conclude that p53 induction and phosphor-
ylation in response to PALA are mediated primarily through
ATR and CHK1 and that ATM has a minor role at most.
DNA Damage and p53 Activation only in Actively Dividing Cells.
Because treatment with PALA inhibits de novo pyrimidine
nucleotide synthesis, cells are most likely to be vulnerable during
S phase, when they require large amounts of dCTP and dTTP for
DNA synthesis. Consequently, it is logical that cells should be
growing for PALA to induce DNA damage. To test this point,
actively growing BJ cells were compared with confluent cells.
After PALA treatment, only the growing cells showed an
increased level of p53 (Fig. 4A). Actively growing cells did incur
DNA damage (46% comet-positive cells; Fig. 4B). In contrast,
there was very little DNA damage (4–6% comet-positive cells)
and no induction of p53 in confluent cells. Actively growing cells
were shown to incorporate much more BrdU than confluent BJ
cells, as expected (data not shown). Moreover, BJ cells grown in
complete media with 250 M PALA plus 100 mM uridine did
not induce p53 or p21 (data not shown), as expected because
uridine bypasses the PALA-mediated block to pyrimidine nu-
cleotide biosynthesis. These observations support the conclusion
that PALA induces DNA damage only in actively dividing cells
that are starved for pyrimidine nucleotides but not in arrested
cells or cells that are not starved.
Induction and Activation of p53 in Cells Traversing Through S Phase.
Based on the above findings, we propose that PALA causes DNA
damage only when cells are in S phase. BJ cells were synchro-
nized by serum starvation for 36 h and, at time 0, the block was
released by adding fresh medium and uridine-free serum. The
cells were treated with 250 M PALA 12 h after release,
harvested 0, 12, 14, 16, 18, 20, 22, 24, and 36 h after release and
analyzed for the expression of p53 and two p53 target proteins.
Cell cycle analysis showed that30% of the cells were in S phase
after 20 h, and60%were in G1 after 36 h (data not shown). The
amount of p53 increased 22 h after release and remained high up
to 36 h (Fig. 5). Phosphorylation of p53 on serine 15 and CHK1
on serine 345 was also elevated, in parallel with total p53 (Fig.
5). Interestingly, protein (Fig. 5A) and RNA (data not shown)
expression of the p53 target genes p21 and MIC-1 was increased
only 36 h after synchronization and not after 22 h. We conclude
that PALA induces DNA damage in S phase, when unbalanced
pools of deoxynucleoside triphosphates are likely to stimulate
mismatch repair. However, p53 target genes are not up-regulated
in S phase, where p53 is transcriptionally inactive (19). Only after
cells reach G2 can p53 induce the expression of p21 and MIC-1,
which, in turn, are responsible for G1/G2 and S phase arrest,
respectively, as discussed below.
A different experiment was done to determine how soon after
PALA treatment perturbation of the cell cycle became evident.
Growing BJ cells were pulse-labeled with BrdU for 30 min,
followed by a thymidine chase and administration (or not) of 250
M PALA. Cells were trypsinized and fixed at various times,
followed by staining with anti-phospho-S780-Rb (to mark mi-
totic cells), anti-BrdU, and DAPI, and analyzed kinetically (20,
21). For the first 24 h there was no significant difference between
the PALA-treated and untreated cell populations: The S-phase
transit times were 6.5 and 6.6 h (not statistically different) for the
treated and untreated cells, respectively; nor were there differ-
ences in G1, G2, or M phase times (data not shown). Note that
the activation of p53 in PALA-treated cells is very strong at 24 h
(Fig. 2), clearly showing that p53 activation occurred well before
the rate of DNA synthesis is affected by PALA. However, at 48 h
A
p53
BJ + DMSO BJ + UCN-01
actin
CHK1-pSer345
h, PALA0     12    24   48 0     12    24    48
B
CHK1-pSer345
ATR WT ATR KD
p53
actin
h, PALA0     12    24   48 0     12    24    48
C
p53
actin
ATM Null
CHK1-pSer345
h, PALA0   12  24  48
Fig. 3. ATR- but not ATM-dependent increase in the phosphorylation of p53
and CHK-1. (A) Western analysis of phosphorylated CHK1 and p53. BJ cells
were pretreated with UCN-01 or solvent (DMSO) for 45 min and then treated
with 250M PALA for 12–48 h. (B) Total p53 and phosphorylated CHK1 in ATR
WT (U2OS) and ATR KD cells treated with 250 M PALA. (C) Total p53 and
phosphorylated CHK1 in ATM-null primary fibroblasts treated with 250 M
PALA.
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Fig. 4. DNA damage and p53 activation in actively dividing cells. (A) Expres-
sion of p53 in actively growing or confluent BJ cells treated with 250M PALA.
The Western procedure was used for analysis. (B) DNA damage, measured by
comet assay in actively growing or confluent BJ cells treated with 250 M
PALA. One hundred cells were counted for each time point.
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there were many more cells in S phase in the PALA-treated
samples than in the control samples, with a skewing toward late
S phase (Fig. 5B), indicating an abnormal S phase in which cells
are accumulating late. These results are consistent with a model
in which, in normal cells with wild-type p53, the skewing of
deoxynucleoside triphosphate pools in response to PALA cre-
ates reversible DNA damage, sufficient to activate p53 and thus
to activate secondarily the expression of proteins that provide
protective arrest at multiple points in the cell cycle. Taken
together, these events occur before the deoxynucleoside triphos-
phate pools become depleted enough in response to PALA to
cause a substantial decrease in the rate of DNA synthesis and
related changes in S phase transit. As shown by earlier studies
(13), in cells in which p53 is absent or in which the p53 pathway
is compromised, failure to arrest DNA synthesis when pyrimi-
dine nucleoside triphosphate pools are depleted leads to irre-
versible DNA damage that eventually causes apoptosis.
Discussion
Treatment of cells with PALA blocks de novo pyrimidine
nucleotide biosynthesis and induces growth arrest of normal
mammalian fibroblasts (8, 10). When nucleotide pools become
unbalanced, a signal is activated that leads to the induction and
activation of p53. The activated p53, in turn, leads to reversible,
long-term cell cycle arrest. By analyzing metaphase spreads,
Linke et al. (2) found no evidence for DNA breaks in PALA-
treated normal human fibroblasts. However, several questions
remain unanswered: How is p53 activated in response to star-
vation for pyrimidine nucleotides? Which p53-dependent signals
trigger protective arrest in S phase? By what mechanisms are cell
growth and DNA replication arrested for many days without
irreversible damage to DNA in normal cells? Although the
expression of MIC-1 has been reported to be both p53-
dependent and -independent (22, 23), our recent work has
identified MIC-1 as a p53 target that has a major role in
protecting cells in S phase (13). The detailed mechanism of
MIC-1-dependent protective arrest remains to be explored. The
results of the current study deal with the issue of how p53 is
activated in response to treatment with PALA.
We studied whether PALA treatment causes any DNA dam-
age by using analyses different from those used by Linke et al. (2).
Comet and H2AX assays revealed that starvation for pyrimi-
dine nucleotides does lead to DNA damage that is generated
only during S phase. The damage then triggers the phosphory-
lation of p53 at serine residues, prompting us to examine proteins
known to play a role in the activation of p53 in response to DNA
damage. The serine/threonine kinases CHK1 and CHK2 share
overlapping functions in controlling both the S and G2/M
checkpoints. CHK1 is activated by ATR through the phosphor-
ylation of serine residues 317 and 345. On the other hand, CHK2
is activated by the related kinase ATM. ATM is activated
primarily after double-strand breaks in DNA, whereas ATR
seems to be critical for cellular responses to the arrest of
replication forks and single-strand breaks in DNA (24). Signals
from broken DNA use the ATM/ATR–CHK1/2–cdc25 pathway
to stabilize and phosphorylate p53. In the current study, by using
a specific inhibitor of CHK1 and ATR KD cells, we found that
the signal from the DNA damage induced in response to PALA
uses the ATR/CHK1 pathway to modulate p53 activity. There is
no obvious difference in the level of expression of p53 protein in
ATM-null cells, ruling out a substantial role of ATM in the
activation of p53 under the conditions studied. Consistent with
the absence of double-strand breaks is the observation that
starvation for pyrimidine nucleotides leads to limited DNA
damage, which then serves as a signal for p53 induction and
activation. It is significant that cells that express p53 survive this
limited damage, again arguing for a lack of double-strand breaks.
Cells lacking p53, when starved for pyrimidine nucleotides,
attempt to synthesize DNA, as revealed by strong incorporation
of BrdU, under highly unfavorable conditions when pyrimidine
deoxynucleoside triphosphate pools are very low and thus incur
irreversible, extensive DNA damage, triggering apoptosis (13).
A careful examination of the progression of BrdU-
incorporated cells through the cell cycle (Fig. 5), where cells
accumulate in the second S phase after PALA treatment, is
consistent with a model in which the skewing of deoxynucleoside
triphosphate pools in response to PALA creates reversible DNA
damage, sufficient to activate p53. This activated p53 then
transactivates secondarily the expression of proteins that provide
protective arrest at multiple points in the cell cycle. These events
occur before the deoxynucleoside triphosphate pools become
depleted enough to cause a substantial decrease in the rate of
DNA synthesis. As shown by earlier studies (8, 13), in cells in
which p53 is absent or in which the p53 pathway is compromised,
failure to arrest DNA synthesis when pyrimidine nucleoside
triphosphate pools are depleted leads to irreversible DNA
damage that eventually causes apoptosis.
We propose a comprehensive model to explain the role p53
plays when pyrimidine nucleotide pools are depleted in response
to PALA (Fig. 6). It is very likely that an increased frequency of
misincorporation caused by unbalanced pools leads to an in-
crease in mismatch repair, and that this reversible form of DNA
damage occurs while cells progress through the first round of
DNA synthesis. Our current observations indicate that the initial
DNA damage occurs slowly and only in actively dividing cells.
We propose that this form of DNA damage is sufficient to
generate a signal for the phosphorylation and subsequent sta-
bilization of p53 through the activities of ATR and CHK1, not
ATM, which responds to more substantial DNA damage, such as
double-strand breaks. As reported earlier (19), p53 remains
transcriptionally inactive during S phase. From our analysis of
the cell cycle and the kinetics of the activation of p53 and its two
target proteins p21 and MIC-1, we conclude that p53 is activated
well before DNA synthesis slows down because of depletion of
p53- pSer15
MIC-1
CHK1-pSer345
p53
p21
- - +     +      +     +     +     +      +      +    PALA treatment
actin
0         12      14    16   18    20   22    24    36   hours after release
Untreated, 48h PALA, 48h
DNA content
B
A
Fig. 5. Induction and activation of p53 in cells traversing through S phase. (A)
BJ Tert cells were serum-starved for 36 h and, after synchronization, fresh
medium with dialyzed serum was added. Ten hours after release, the cells
were treated with 250 M PALA and harvested after 12–36 h. Lysates of
treated cells were analyzed by Western analysis for phosphorylated CHK1,
p53, p53-ser15, p21, and MIC-1. (B) Growing BJ cells (60–70% confluent) were
stained with 20 M BrdU for 30 min followed by 100 M thymidine chase for
an additional 30 min. Cells were then treated with 250M PALA and harvested
for cell cycle analysis at different time points.
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pyrimidine deoxynucleoside triphosphates, and that only when
the cells exit from the first S phase and enter the next cell cycle
does the activated p53 becomes transcriptionally competent,
eventually activating G2, G1, and S phase checkpoints by acti-
vating the expression of key regulatory proteins such as p21 and
MIC-1.
PALA kills fibroblasts lacking p53 but not fibroblasts that
express wild-type p53. Because virtually all cancer cells have
some disruption of p53 function, the properties of PALA seem
ideal for an antitumor drug, and early studies in cell culture and
in animal models showed PALA to be an effective antitumor
agent (25). However, because of dose-limiting gut toxicity,
PALA was not useful in patients. Unfortunately normal human
gut epithelial cells are much more sensitive to PALA than are
normal human fibroblasts. The basis of this difference is not well
understood. Our recent work and ongoing studies have clearly
identified the secretory cytokine, MIC-1, as an important factor
in effecting a p53-dependent protective mechanism and thus
providing a new direction in re-evaluating the use of PALA in
treating cancer (13).
Materials and Methods
Cell Lines and Treatments. Normal human fibroblast BJ cells were obtained
from the American Type Culture Collection. BJ-Tert cells were derived by
retrovirus-mediated introduction of the Tert subunit of human telomerase.
ATR WT and ATR KD cells and AT-null primary human fibroblasts were kind
gifts of David Boothman (University of Texas Southwestern, Dallas) (26). Cell
lines containing a neo marker were grown in the presence of 600 g/ml G418
(Sigma). All cells were grown in 10% CO2 in DMEM supplemented with 10%
FBS. The cells were treated with 250 M PALA.
PALA and CHK1 Inhibitor. PALA (NSC224131), an inhibitor of the aspartate
transcarbamylase activity of the multifunctional enzyme CAD, was obtained
from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics
Program, National Cancer Institute (Bethesda, MD). Cells were treated with
PALA as described by Agarwal et al. (8). For each cell type, the ID50 was
determined, and selection of 2  105 cells per 10-cm plate was done in the
presence of 10% (vol/vol) dialyzed FCS, using PALA at 3  ID50. The selective
medium was changed every 4–5 days. The CHK1 inhibitor UCN-01 was a kind
gift of Robert Shultz (Department of Developmental Therapeutics, National
Cancer Institute). BJ cells were pretreated with 300 nM UCN-01 for 45 min.
Comet Assay. BJ cells were treated with 250 M of PALA in dialyzed serum for
24 or 48 h, and the assay was performed according to the manufacturer’s
protocol (Trevigen). Briefly, cells were gently scraped into the medium,
counted, and washed in ice-cold 1 PBS (free of Ca2 and Mg2). After
washing, the cells (1 105/ml) were suspended in cold PBS and combined with
molten LMAgarose (Trevigen) at 37°C at a ratio of 1:10 (vol/vol). Seventy-five
microliters of the mixture was spread onto a slide and allowed to solidify at 4°C
in the dark for a minimum of 10 min. Cells were lysed by immersing the slides
in prechilled lysis solution for 30–60 min, after which the cells were immersed
in a freshly prepared alkaline solution (pH13) for 20–60 min. The slides were
then washed with 1 Tris-borate-EDTA buffer and run on a horizontal elec-
trophoresis apparatus (1 V/cm) for 10 min. The slides were washed in 70%
ethanol, air-dried, and kept in the dark until analysis. Cells were visualized by
adding 50l of diluted SYBR green 1 (excitation and emission, 494 nm and 521
nm, respectively) and observed by epifluorescence microscopy.
H2AX Staining. BJ cells (1,500 cells per chamber) were plated overnight in
DMEM with dialyzed serum and then treated with 250 M of PALA for 0, 1, 2,
3, 6, 12, 24 or 48 h. The following controls were used: primary antibody alone,
isotype control, secondary antibody alone, and 1 M etoposide for 3 h as a
positive control. After treatment the cells were fixed in 4% paraformaldehyde
in TBS buffer and stained overnight in primary anti-H2AX (1:500 dilution; Cell
Signaling) After overnight incubation, the cells were washed a few times with
TBS/BSA and incubated for 1 h with anti-rabbit secondary antibody conju-
gated with Alexa 488 (Invitrogen). The cells were washed and fixed in Prolong
Gold Antifade with DAPI (Invitrogen) and stored at 4°C for 24 h (as recom-
mended) before examining the slides. Pictures were taken by using a Nikon
Eclipse E 800 microscope with attached camera and using Spot Software
(Diagnostic Instruments). Images were taken at20 (20/0.75 DIC M Plan APO
lens), except that the images in the Fig. 1 Insets were taken with a 40 lens
(40/1.0 DIC H Plan APO oil immersion lens). Objectives were set at wave-
lengths of 488 nm for Alexa 488 and 350 nm for DAPI.
Western Analyses. Total cellular protein was isolated by lysing cells in 20 mM
TrisHCl (pH 7.5), 2% (wt/vol) SDS, 2 mM benzamidine, and 0.2 mM phenyl-
no p53
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gene activation
Long term, stable
G1 & G2 arrest
Minor DNA damage during
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Primary gene activation by p53 
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Fig. 6. Activation of p53 and its effects on cell cycle checkpoints in response to PALA.
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methanesulfonyl fluoride. Protein concentrations were determined by the
Bradford method (Bio-Rad). Proteins (25 g per lane) were separated by
SDS/10% PAGE) and electro-blotted onto polyvinylidene difluoride mem-
branes (Stratagene). The membranes were probed with antibodies against
p53, p21 (Santa Cruz Biotechnology), phosphoserine p53, phosphoserine
CHK1 (Cell Signaling Technology), or actin (Labvision), followed by incubation
with anti-mouse or anti-rabbit secondary antibody-horseradish peroxidase
conjugate (Amersham Life Sciences). Chemiluminescence was developed by
using an ECL kit (Amersham Life Sciences).
Cell Cycle Analyses. Growing BJ cells were plated (2  106 cells per plate) and
grown overnight (60–70% confluent). Cells were then incubated with 20 M
BrdU for 30 min followed by two washes with PBS. Ten milliliters of media with
100M thymidine was added, and cells were incubated for 30 min. At the end,
the plates were again washed twice with 1 PBS. Then DMEM with 10%
dialyzed serum was added for PALA-treated cells and normal DMEM with 10%
FBS for untreated cells. Cells were then treated with 250 M PALA and
harvested for cell cycle analysis at different time points.
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